Alliance for Regenerative Medicine Announces Agenda for Regen Med Investor Day

- Taking place April 17, 2013 in New York City; Agenda includes keynote talks, focused disease sessions with KOL participation and presentations from 16 top regenerative medicine companies -

News provided by

Alliance for Regenerative Medicine

Mar 12, 2013, 09:34 ET

WASHINGTON, March 12, 2013 /PRNewswire/ -- The Alliance for Regenerative Medicine (ARM) today announced the agenda for its Regen Med Investor Day, the first investor event organized specifically for the regenerative medicine sector. The event will take place on April 17 at the Harmonie Club, 4 East 60th Street, New York, NY.

This one-day, high-impact program will provide institutional investors and life science analysts with insight from the industry's leading small- and mid-cap companies as well as exclusive access to regenerative medicine's top stakeholders.

Credentialed investors, life science strategic partners and members of the media should contact Laura Parsons at [email protected] if interested in attending.

7:30am    

Breakfast & Networking

8:00am    

Welcome Remarks

8:10am      

Keynote Talk - Kieran Murphy, VP, President & CEO, GE Healthcare Life Sciences

8:30am        

Keynote Talk - Jeff Jonas, President, Shire Regenerative Medicine

8:50am        

Program Introduction - Jason Kolbert, Senior Biotechnology Analyst, Maxim Group

9:00am        

Clinical Outlooks in Cardiovascular Disease

Jason Kolbert, Senior Biotechnology Analyst, Maxim Group (moderator)

Douglas Losordo, MD, Adjunct Professor in Medicine-Cardiology, Northwestern University

Eduardo Marban, MD, Director, Cedars-Sinai Heart Institute

Leslie Miller, MD, Chair, College Of Medicine Dean's Office, University of South Florida

9:55am    

Break

10:10am    

Regenerative Medicine in Wound Healing & Tissue Engineering

Ted Tenthoff, Managing Director & Senior Biotechnology Analyst, Piper Jaffray (moderator)

Vincent Falanga, MD, Professor, Boston University School of Medicine

Will Li, MD, President & Medical Director, The Angiogenesis Foundation

Thomas Serena, MD, FACS, CEO and Medical Director SerenaGroup

11:05am  

Therapeutics for a Broad Range of CNS Diseases

Ren Benjamin, Ph.D., Managing Director & Senior Biotechnology Analyst, Burrill & Company (moderator)

Sean Savitz, MD, Professor of Neurology, University of Texas Medical School, UTHealth

12:00pm  

Plated Lunch & Networking

12:45pm    

Lunchtime Presentation - G. Steven Burrill, CEO, Burrill & Company

1:00pm        

Cytori Therapeutics - Chris Calhoun, CEO

1:15pm          

Athersys - Gil Van Bokkelen, Chairman & CEO

1:30pm      

Mesoblast - Silviu Itescu, CEO & President

1:45pm      

Juventas Therapeutics - Rahul Aras, President & CEO

2:00pm      

Aastrom Biosciences - Dan Orlando, Chief Commercial Officer

2:15pm      

NeoStem - Robin Smith, Chairman & CEO

2:30pm      

Pluristem Therapeutics - Zami Aberman, Chairman & CEO

2:45pm      

Cytomedix - Martin Rosendale, CEO

3:00pm      

Afternoon Break

3:15pm      

Sangamo BioSciences - Edward Lanphier, President & CEO

3:30pm        

BioTime Acquisition Corp - Thomas Okarma, President & CEO 

3:45pm    

Advanced Cell Technology (ACT) - Gary Rabin, Chairman & CEO

4:00pm    

StemCells Inc. - Martin McGlynn, President & CEO

4:15pm      

Organogenesis - Geoff MacKay, President & CEO

4:30pm      

Organovo - Keith Murphy, CEO

4:45pm      

Tigenix - Eduardo Bravo, CEO

5:00pm      

Mimedx - Michael Senken, CFO

5:15pm      

Program Wrap-up - Ted Tenthoff, Managing Director & Senior Biotechnology


Analyst, Piper Jaffray

5:30pm  

Networking Reception

This meeting is co-hosted by leading financial firms Burrill & Company, Piper Jaffray and Maxim Group and in partnership with Life Science Advisors and Blaise Group International.

The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit www.alliancerm.org.

Media Contact:
Michelle Linn
Linnden Communications
Phone: 508-362-3087

SOURCE Alliance for Regenerative Medicine